Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer

Fig. 6

Effects of Nano-DOX and DOX on the expression of IL-6 in 4T1 cells and the effect of IL-6 on apoptosis in 4T1 cells treated with Nano-DOX or DOX. a RT-PCR assay of IL-6 mRNA levels in in vitro 4T1 cells treated with Nano-DOX or DOX. b ELISA analysis of IL-6 secretion from in vitro 4T1 cells treated with Nano-DOX or DOX. c Immunohistochemical staining of IL-6 in 4T1 tumor xenografts at the end of 3-week treatment of Nano-DOX or DOX. d, e Effect of IL-6 silence on apoptosis in in vitro 4T1 cells treated with Nano-DOX or DOX, assayed by immunostaining and FACS. f Verification of IL-6 knock-down at the mRNA level, assayed by RT-PCR. g, h Rescue effect of exogenous IL-6 on DOX-induced apoptosis in in vitro 4T1 cells with IL-6 knock-down, assayed by immunostaining and FACS. I: Rescue effect of exogenous IL-6 on DOX-induced Bcl-2 mRNA downregulation in in vitro 4T1 cells with IL-6 knock-down, assayed by RT-PCR. Duration of Nano-DOX or DOX treatment was 24 h for the in vitro cell experiments. In FACS analysis, geometric means were used to quantify fluorescence intensity. Values were mean ± SD (n = 3, *p < 0.05, **p < 0.01)

Back to article page